期刊
JOURNAL OF THE ENDOCRINE SOCIETY
卷 4, 期 10, 页码 -出版社
ENDOCRINE SOC
DOI: 10.1210/jendso/bvaa114
关键词
autoimmune diabetes; type 1 diabetes; intratumoral immunotherapy; T-VEC; immune toxicity; immune-related adverse events
资金
- American Diabetes Association [1-19-PDF-131]
- NHMRC C.J. Martin Fellowship [1143981]
- National Cancer Institute of the National Institutes of Health [K99CA246061]
- National Health and Medical Research Council of Australia [1143981] Funding Source: NHMRC
Cancer immunotherapies are changing the landscape of cancer care. Intratumoral talimogene iaherparepvec (T-VEC), an oncolytic viral vaccine, has been approved for treatment of unresectable melanoma with minimal toxicity. We describe the first case of a centenarian who developed autoimmune diabetes while on T-VEC immunotherapy. The patient's high titer of glutamic acid decarboxylase 65 autoantibodies as well as insulin deficiency are consistent with autoimmune diabetes. Autoimmune diabetes has previously been seen following immune checkpoint inhibitor use; however, it has never been reported with T-VEC. This case highlights that autoimmune diabetes can be a rare but morbid complication of intratumoral T-VEC immunotherapy and can occur in the ultra-elderly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据